Premium
The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients
Author(s) -
Uyanik Mehmet S.,
Pamuk Gulsum E.,
Maden Muhammet,
Merev Elif,
Cevik Gokcen,
Uyanik Vesile,
Umit Elif G.,
Demir Ahmet M.,
Akker Mustafa
Publication year - 2017
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12423
Subject(s) - medicine , discontinuation , chronic myeloid leukaemia , quality of life (healthcare) , imatinib mesylate , anxiety , depression (economics) , imatinib , psychiatry , myeloid leukemia , nursing , economics , macroeconomics
Treatment with tyrosine kinase inhibitors ( TKI s) has dramatically changed the life expectancy of chronic myeloid leukaemia ( CML ) patients. Although the impact of first‐generation TKI s on quality of life (QoL) was shown in CML , the effects of new generic formulations of imatinib mesylate ( IM ) are unclear. We evaluated differences in QoL under treatment with first‐ or second‐generation TKI s. Fifty‐two patients diagnosed with CP ‐ CML completed the European Organization for Research and Treatment of Cancer Quality of Life Questionaire‐C30, Hospital Anxiety and Depression Scale, and General Health Questionnaire. General QoL scores were similar between groups. There was a significant difference in the frequency of diarrhoea between IM group and the group using new generic formulations of IM ( P = 0.012). General QoL score tended to be higher in patients with disease duration longer than 3 years ( P = 0.052). GHQ , anxiety and depression scores correlated positively with symptom scales and negatively with functional subscales. CML patients using new generic formulations of IM reported a higher frequency of diarrhoea than patients using original IM and second‐generation TKI s that could result in more drug discontinuation.